title: Effect of polymyxin B-immobilized fiber on blood metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in acute respiratory distress syndrome patients.
abstract: OBJECTIVE
  Metalloproteinase (MMP)-9 plays a role in the pathogenesis of acute respiratory distress syndrome (ARDS). Polymyxin B-immobilized fiber (PMX-F) treatment improves circulatory disturbance and oxygenation in ARDS patients. We aimed to assess whether PMX-F treatment alters the blood MMP-9 and tissue inhibitor of MMP (TIMP)-1 levels in ARDS patients.
  
  
  METHODS
  Twelve ARDS patients who received PMX-F treatment and 20 healthy control volunteers were included in this study. PMX-F was carried out twice at a rate of 100 ml/min for 2 h with a time interval of 24 h. Blood MMP-9 and TIMP-1 levels were measured before and after PMX-F treatment. We monitored blood pressure and the PaO2/FiO2 (PF) ratio before and after PMX-F treatment.
  
  
  RESULTS
  The mortality of ARDS patients after PMX-F treatment was 16.7%. Chest X-ray abnormalities were ameliorated in surviving patients after PMX-F treatment. Systolic and diastolic blood pressure increased significantly after PMX-F treatment (p < 0.01). The PF ratio also increased significantly after PMX-F treatment (p < 0.01). Blood MMP-9 and TIMP-1 levels in ARDS patients (126.4 +/- 36.4 and 326.5 +/- 52.5 ng/ml) were significantly higher than in controls (34.5 +/- 12.5 and 160.5 +/- 24.5 ng/ml; p < 0.01). PMX-F treatment reduced these levels significantly (the first treatment: MMP-9 85.4 +/- 28.6 ng/ml, p < 0.05, TIMP-1 265.8 +/- 36.6 ng/ml, p < 0.05; the second treatment: MMP-9 56.5 +/- 18.8 ng/ml, p < 0.01, TIMP-1 220.6 +/- 30.5 ng/ml, p < 0.01).
  
  
  CONCLUSIONS
  These data suggest that MMP-9 and TIMP-1 may play a role in the pathogenesis of ARDS and that PMX-F treatment ameliorated increased MMP-9 and TIMP-1 levels in ARDS patients.
authors.affiliation: Department of Medicine, Shinmatsudo Central General Hospital, Chiba, Japan.
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Nakamura
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Kawagoe
authors.forename: Takaharu
authors.initials: T
authors.lastname: Matsuda
authors.forename: Hisataka
authors.initials: H
authors.lastname: Shoji
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Ueda
authors.forename: Naoaki
authors.initials: N
authors.lastname: Tamura
authors.forename: Isao
authors.initials: I
authors.lastname: Ebihara
authors.forename: Hikaru
authors.initials: H
authors.lastname: Koide
mesh_terms: D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D004731:Endotoxins / Q000097:blood; D005260:Female; D006464:Hemoperfusion / Q000379:methods; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood* / Q000187:drug effects; D008875:Middle Aged; D011112:Polymyxin B / Q000494:pharmacology* / Q000627:therapeutic use; D012128:Respiratory Distress Syndrome / Q000097:blood / Q000401:mortality / Q000628:therapy*; D012129:Respiratory Function Tests; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood* / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D004731:Endotoxins; D019715:Tissue Inhibitor of Metalloproteinase-1; D020780:Matrix Metalloproteinase 9; D011112:Polymyxin B